The goal of this clinical trial is to evaluate the safety and potential efficacy of PNEUMOSTEM® for improving respiratory outcomes in very premature infants diagnosed with Early Pulmonary Arterial Hypertension. The main questions it aims to answer are: * In very premature infants diagnosed with early pulmonary arterial hypertension, will a single intratracheal administration of PNEUMOSTEM®(Allogeneic umbilical cord blood-derived mesenchymal stem cells) result in improvement of pulmonary arterial hypertension based on echocardiographic assessment? * In very premature infants diagnosed with early pulmonary arterial hypertension who show improvement of pulmonary arterial hypertension based on echocardiographic assessment following a single intratracheal administration of PNEUMOSTEM®(Allogeneic umbilical cord blood-derived mesenchymal stem cells), at what time point does this improvement occur? Participants will: * Single intratracheal dose of PNEUMOSTEM® at 2.0 x 10,000,000 cells/kg * Acute adverse event monitoring: 24 hours post-administration for safety assessment * Follow- up time points: Day 1(Baseline, PNEUMOSTEM® administration), Day 2, Week 1, Week 2, Postnatal Day 28, PMA 36\~40 weeks
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Time point(week) of complete reversal of cardiac shunt direction
Timeframe: Biweekly from day after PNEUMOSTEM administration until postnatal day 28
Time to normalization of ventricular septal configuration
Timeframe: Once between postnatal day 28 and PMA 36~40 weeks
Change in duration of pulmonary hypertension medication use
Timeframe: Daily on PNEUMOSTEM administration day and the next day
Change in duration of mechanical ventilation
Timeframe: Weekly at week 1 and week 2 after PNEUMOSTEM administration
Change in duration of supplemental oxygen therapy.
Timeframe: Weekly at week 1 and week 2 after PNEUMOSTEM administration
Incidence of Bronchopulmonary Dysplasia(BPD)
Timeframe: At postnatal day 28 and at between PMA 36~40 weeks
Severity of Bronchopulmonary Dysplasia(BPD)
Timeframe: At postnatal day 28 and at between PMA 36~40 weeks
Incidence of Retinopathy of Prematurity(ROP)
Timeframe: Once at between PMA 36~40 weeks
Severity of Retinopathy of Prematurity(ROP)
Timeframe: Once at between PMA 36~40 weeks
Time point of brain injury ditection on Brain MRI
Timeframe: Once at between PMA 36~40 weeks
Incidence of Respiratory-related mortality
Timeframe: From PNEUMOSTEM administration to PMA 36~40 weeks
Tiem point of respiratory-related mortality
Timeframe: From PNEUMOSTEM administration to PMA 36~40 weeks